Novogen banks on beans for a healthy market: a pharmaceutical company hopes that a derivative of legumes will fight cancer and boost the bottom line
Article Abstract:
Independent research indicates that NV-06, developed by Australian biopharmaceutical firm Novogen, blocks the growth of human prostate cancer cells transplanted into mice. The company's research into legume-based drugs is discussed.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Treasure hunters
Article Abstract:
Gene mapping technology is becoming increasingly popular with investors, but it is an extremely volatile area of the biotechnology market.
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: When the thrill has gone. From a tiny molecule, mighty hopes spring
- Abstracts: Setting tolerable misstatements when auditing aggregated accounts. Modeling the audit opinions issued to bankrupt companies: A two-stage empirical analysis
- Abstracts: Don't blink, you might miss something. Perils of forecasting. The ever-growing options for investing
- Abstracts: ... If it ain't got that swing. Aussie cossies lure US Internet surfers. On your marks ...
- Abstracts: Collaborating to compete: benchmarking through regional partnerships. Knowledge management: the way forward